ELI LILLY & Co is 384.7x more valuable than Arcus Biosciences, Inc. by market capitalization ($1.070 T vs $2.78 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RCUS | LLY |
|---|---|---|
| Market cap | $2.78 B | $1.070 T |
| US-listed rank | #1869 | #10 |
| Revenue (latest FY) | $247.00M | $65.18B |
| Net income (latest FY) | -$353.00M | $20.64B |
| Net margin | -142.9% | 31.7% |
| P/E (trailing FY) | - | 51.8 |
| SEC filings | 567 | 989 |
ELI LILLY & Co is 384.7x more valuable than Arcus Biosciences, Inc. by market capitalization ($1.070 T vs $2.78 B).
In their latest fiscal years, Arcus Biosciences, Inc. reported $247.00M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Arcus Biosciences, Inc. and ELI LILLY & Co, or browse the full rankings.